Document ID: BIS-2016-0020-0001
Agency: bis
Document Type: Rule
Title: Implementation of the February 2015 Australia Group Intersessional Decisions and the June 2015 Australia Group Plenary Understandings
Posted Date: 2016-06-07T04:00Z

[Federal Register Volume 81, Number 109 (Tuesday, June 7, 2016)]
[Rules and Regulations]
[Pages 36458-36463]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-13271]

-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Bureau of Industry and Security

15 CFR Parts 710, 745, and 774

[Docket No. 160302176-6176-01]
RIN 0694-AG88

Implementation of the February 2015 Australia Group (AG) 
Intersessional Decisions and the June 2015 AG Plenary Understandings

AGENCY: Bureau of Industry and Security, Commerce.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Bureau of Industry and Security (BIS) publishes this final 
rule to amend the Export Administration Regulations (EAR) to implement 
the recommendations presented at the February 2015 Australia Group (AG) 
intersessional implementation meeting, and later adopted pursuant to 
the AG silent approval procedure, and the understandings reached at the 
June 2015 AG Plenary meeting. This rule amends three Commerce Control 
List (CCL) entries to reflect the February 2015 intersessional 
recommendations that were adopted by the AG. Specifically, this rule 
amends the CCL entry that controls chemical precursors by adding the 
chemical diethylamine (C.A.S. 109-89-7), which was not previously 
identified on the AG's ``Chemical Weapons Precursors'' common control 
list. This rule also amends the CCL entry that controls certain human 
and zoonotic pathogens and toxins by adding two viruses that were not 
previously identified on the AG ``List of Human and Animal Pathogens 
and Toxins for Export Control'' and by updating the nomenclature of 
certain viruses that were already identified on this AG common control 
list. In addition, this rule amends the CCL entry that controls 
equipment capable of handling biological materials to reflect the AG 
intersessional updates to the controls on biocontainment chambers, 
isolators, and biological safety cabinets and the controls on aerosol 
inhalation equipment described on the AG ``Control List of Dual-Use 
Biological Equipment and Related Technology and Software.'' Consistent 
with the understandings adopted at the June 2015 AG Plenary meeting, 
this rule also amends the CCL entry that controls equipment capable of 
handling biological materials by updating the controls on freeze-drying 
(lyophilization) equipment.
    Finally, this rule amends the EAR to reflect the addition of Angola 
and Burma as States Parties to the Chemical Weapons Convention (CWC) 
and also amends the Chemical Weapons Convention Regulations (CWCR) to 
reflect the addition of these two countries as States Parties.

DATES: This rule is effective June 7, 2016.

FOR FURTHER INFORMATION CONTACT: Richard P. Duncan, Ph.D., Director, 
Chemical and Biological Controls Division, Office of Nonproliferation 
and Treaty Compliance, Bureau of Industry and Security, Telephone: 
(202) 482-3343, Email: Richard.Duncan@bis.doc.gov.

SUPPLEMENTARY INFORMATION: The Bureau of Industry and Security (BIS) is 
amending the Export Administration Regulations (EAR) to implement the 
recommendations presented at the Australia Group (AG) Intersessional 
meeting held in The Hague, Netherlands, on February 4, 2015, and 
adopted pursuant to the AG silent approval procedure in April 2015, and 
the understandings reached at the AG Plenary meeting held in Perth, 
Australia, from June 1-5, 2015. The AG is a multilateral forum 
consisting of 41 participating countries that maintain export controls 
on a list of chemicals, biological agents, and related equipment and 
technology that could be used in a chemical or biological weapons 
program. The AG periodically reviews items on its control list to 
enhance the effectiveness of participating governments' national 
controls and to achieve greater harmonization among these controls.

Amendments to the CCL Based on the February 2015 AG Intersessional 
Recommendations

    This rule amends three Export Control Classification Numbers 
(ECCNs) on the Commerce Control List (CCL) (see Supplement No. 1 to 
part 774 of the EAR), as described below, to reflect the February 2015 
intersessional recommendations that were adopted by the AG.

Amendments to ECCN 1C350 (Precursor Chemicals)

    This final rule amends ECCN 1C350 on the CCL, to reflect the 
addition of the chemical diethylamine (C.A.S. 109-89-7) to the AG's 
``Chemical Weapons Precursors'' common control list, by adding this 
chemical to 1C350.d, which controls precursor chemicals identified on 
the AG common control list that are not also ``scheduled'' chemicals 
(i.e., chemicals identified as Schedule 1, Schedule 2, or Schedule 3 
chemicals) under the Chemical Weapons Convention (CWC).
    Like the other precursor chemicals controlled under ECCN 1C350.d, 
diethylamine requires a license for chemical/biological (CB) reasons to 
destinations indicated under CB Column 2 on the Commerce Country Chart 
(see Supplement No. 1 to part 738 of the EAR) and for anti-terrorism 
(AT) reasons to destinations in Country Group E:1 (see Supplement No. 1 
to part 742 of the EAR). Because none of the precursor chemicals 
controlled under ECCN 1C350.d (including diethylamine) are identified 
as ``scheduled'' chemicals under the CWC, these precursor chemicals do 
not require a license for chemical weapons (CW) reasons. (See part 742 
of the EAR for additional information on the AT controls that apply to 
Iran, North Korea, Sudan, and Syria. See part 746 of the EAR for 
additional information on the sanctions that apply to Iran, North 
Korea, and Syria.)

Amendments to ECCN 1C351 (Human and Animal Pathogens and ``Toxins'')

    This final rule amends ECCN 1C351 on the CCL to reflect the 
addition of two viruses (severe acute respiratory syndrome-related 
coronavirus, a.k.a. SARS-related coronavirus, and reconstructed 1918 
influenza virus) that were not previously identified on the AG ``List 
of Human and Animal Pathogens and Toxins for Export Control'' and to 
update the nomenclature for seventeen viruses that were already 
identified on this AG common control list and in ECCN 1C351.a (nineteen 
viruses were updated on the AG common control list, but only seventeen 
viruses in ECCN 1C351.a required updating). Prior to the publication of 
this final rule, the two viruses that are being added to ECCN 1C351.a 
were listed under ECCN 1C351.b, which controls viruses identified on 
the ``select agents'' lists maintained by the Animal and Plant Health 
Inspection Service (APHIS), U.S. Department of Agriculture, and the 
Centers for Disease Control and Prevention (CDC), U.S. Department of 
Health and Human Services, but not identified on the AG ``List of Human 
and Animal Pathogens and Toxins for Export Control.''
    The license requirements applicable to the viruses affected by the 
amendments in this final rule (including the two viruses that are being 
moved

[[Page 36459]]

from 1C351.b to 1C351.a) remain unchanged. Specifically, all of these 
viruses continue to require a license for CB reasons to destinations 
indicated under CB Column 1 on the Commerce Country Chart and for AT 
reasons to destinations indicated in AT Column 1 on the Commerce 
Country Chart.
    This final rule also makes conforming changes to ECCN 1C351 by 
renumbering certain items in ECCN 1C351.a to reflect the addition of 
the two aforementioned viruses (i.e., the SARS-related coronavirus and 
the reconstructed 1918 influenza virus) and the updates to the 
nomenclature for seventeen other viruses listed in 1C351.a. The 
following table lists the viruses that are controlled under ECCN 
1C351.a, as a result of the amendments made by this final rule, and 
indicates the previous and current names and CCL designations for each 
of these viruses. The names and CCL designations of thirteen viruses 
were not affected by this rule (these viruses continue to be designated 
as 1C351.a.1 through .a.8 and 1C351.a.42 through .a.46, as indicated in 
the following table). Twenty-six additional viruses in 1C351.a, whose 
names are not updated by this rule, have new CCL designations. All 
seventeen of the viruses in 1C351.a whose names are updated by this 
final rule also have new CCL designations, as do the two aforementioned 
viruses that are being moved from 1C351.b to 1C351.a (both of whose 
names are updated, as well).

----------------------------------------------------------------------------------------------------------------
  Previous names of AG-controlled     Current names of AG-controlled        Previous CCL         Current CCL
              viruses                             viruses                   designation          designation
----------------------------------------------------------------------------------------------------------------
African horse sickness virus......  No change.........................  ECCN 1C351.a.1.....  No change.
African swine fever virus.........  No change.........................  ECCN 1C351.a.2.....  No change.
Andes virus.......................  No change.........................  ECCN 1C351.a.3.....  No change.
Avian influenza virus.............  No change.........................  ECCN 1C351.a.4.....  No change.
Bluetongue virus..................  No change.........................  ECCN 1C351.a.5.....  No change.
Chapare virus.....................  No change.........................  ECCN 1C351.a.6.....  No change.
Chikungunya virus.................  No change.........................  ECCN 1C351.a.7.....  No change.
Choclo virus......................  No change.........................  ECCN 1C351.a.8.....  No change.
Congo-Crimean haemorrhagic fever    Crimean-Congo hemorrhagic fever     ECCN 1C351.a.9.....  ECCN 1C351.a.10.
 virus.                              virus.
Dengue fever virus................  Dengue virus......................  ECCN 1C351.a.10....  ECCN 1C351.a.11.
Dobrava-Belgrade virus............  No change.........................  ECCN 1C351.a.11....  ECCN 1C351.a.12.
Eastern equine encephalitis virus.  No change.........................  ECCN 1C351.a.12....  ECCN 1C351.a.13.
Ebola virus.......................  Ebolavirus (includes all members    ECCN 1C351.a.13....  ECCN 1C351.a.14.
                                     of the Ebolavirus genus).
Foot and mouth disease virus......  Foot-and-mouth disease virus......  ECCN 1C351.a.14....  ECCN 1C351.a.15.
Goat pox virus....................  Goatpox virus.....................  ECCN 1C351.a.15....  ECCN 1C351.a.16.
Guanarito virus...................  No change.........................  ECCN 1C351.a.16....  ECCN 1C351.a.17.
Hantaan virus.....................  No change.........................  ECCN 1C351.a.17....  ECCN 1C351.a.18.
Hendra virus (Equine                No change.........................  ECCN 1C351.a.18....  ECCN 1C351.a.19.
 morbillivirus).
Herpes virus (Aujeszky's disease).  Suid herpesvirus 1 (Pseudorabies    ECCN 1C351.a.19....  ECCN 1C351.a.51.
                                     virus; Aujeszky's disease).
Hog cholera virus (syn.: swine      Classical swine fever virus (Hog    ECCN 1C351.a.20....  ECCN 1C351.a.9.
 fever virus).                       cholera virus).
Japanese encephalitis virus.......  No change.........................  ECCN 1C351.a.21....  ECCN 1C351.a.20.
Junin virus.......................  No change.........................  ECCN 1C351.a.22....  ECCN 1C351.a.21.
Kyasanur Forest virus.............  Kyasanur Forest disease virus.....  ECCN 1C351.a.23....  ECCN 1C351.a.22.
Laguna Negra virus................  No change.........................  ECCN 1C351.a.24....  ECCN 1C351.a.23.
Lassa fever virus.................  Lassa virus.......................  ECCN 1C351.a.25....  ECCN 1C351.a.24.
Louping ill virus.................  No change.........................  ECCN 1C351.a.26....  ECCN 1C351.a.25.
Lujo virus........................  No change.........................  ECCN 1C351.a.27....  ECCN 1C351.a.26.
Lumpy skin disease virus..........  No change.........................  ECCN 1C352.a.28....  ECCN 1C351.a.27.
Lymphocytic choriomeningitis virus  No change.........................  ECCN 1C351.a.29....  ECCN 1C351.a.28.
Machupo virus.....................  No change.........................  ECCN 1C351.a.30....  ECCN 1C351.a.29.
Marburg virus.....................  Marburgvirus (includes all members  ECCN 1C351.a.31....  ECCN 1C351.a.30.
                                     of the Marburgvirus genus).
Monkey pox virus..................  Monkeypox virus...................  ECCN 1C351.a.32....  ECCN 1C351.a.31.
Murray Valley encephalitis virus..  No change.........................  ECCN 1C351.a.33....  ECCN 1C351.a.32.
Newcastle disease virus...........  No change.........................  ECCN 1C351.a.34....  ECCN 1C351.a.33.
Nipah virus.......................  No change.........................  ECCN 1C351.a.35....  ECCN 1C351.a.34.
Omsk haemorrhagic fever virus.....  Omsk hemorrhagic fever virus......  ECCN 1C351.a.36....  ECCN 1C351.a.35.
Oropouche virus...................  No change.........................  ECCN 1C351.a.37....  ECCN 1C351.a.36.
Peste des petits ruminants virus..  Peste-des-petits ruminants virus..  ECCN 1C351.a.38....  ECCN 1C351.a.37.
Porcine enterovirus type 9 (syn.:   Swine vesicular disease virus.....  ECCN 1C351.a.39....  ECCN 1C351.a.52.
 swine vesicular disease virus).
Powassan virus....................  No change.........................  ECCN 1C351.a.40....  ECCN 1C351.a.39.
Rabies virus and other members of   No change.........................  ECCN 1C351.a.41....  ECCN 1C351.a.40.
 the Lyssavirus genus.
Reconstructed replication           Reconstructed 1918 influenza virus  ECCN 1C351.b.1.....  ECCN 1C351.a.41.
 competent forms of the 1918
 pandemic influenza virus.
Rift Valley fever virus...........  No change.........................  ECCN 1C351.a.42....  No change.
Rinderpest virus..................  No change.........................  ECCN 1C351.a.43....  No change.
Rocio virus.......................  No change.........................  ECCN 1C351.a.44....  No change.
Sabia virus.......................  No change.........................  ECCN 1C351.a.45....  No change.
SARS-associated coronavirus (SARS-  Severe acute respiratory syndrome-  ECCN 1C351.b.2.....  ECCN 1C351.a.47.
 CoV).                               related coronavirus (SARS-related
                                     coronavirus).
Seoul virus.......................  No change.........................  ECCN 1C351.a.46....  No change.
Sheep pox virus...................  Sheeppox virus....................  ECCN 1C351.a.47....  ECCN 1C351.a.48.
Sin nombre virus..................  Sin Nombre virus..................  ECCN 1C351.a.48....  ECCN 1C351.a.49.

[[Page 36460]]

 
St. Louis encephalitis virus......  No change (correction needed on AG  ECCN 1C351.a.49....  ECCN 1C351.a.50.
                                     common control list, only).
Teschen disease virus.............  Porcine Teschovirus...............  ECCN 1C351.a.50....  ECCN 1C351.a.38.
Tick-borne encephalitis virus       No change (correction needed on AG  ECCN 1C351.a.51....  ECCN 1C351.a.53.
 (Russian Spring-Summer              common control list, only).
 encephalitis virus).
Variola virus.....................  No change.........................  ECCN 1C351.a.52....  ECCN 1C351.a.54.
Venezuelan equine encephalitis      No change.........................  ECCN 1C351.a.53....  ECCN 1C351.a.55.
 virus.
Vesicular stomatitis virus........  No change.........................  ECCN 1C351.a.54....  ECCN 1C351.a.56.
Western equine encephalitis virus.  No change.........................  ECCN 1C351.a.55....  ECCN 1C351.a.57.
Yellow fever virus................  No change.........................  ECCN 1C351.a.56....  ECCN 1C351.a.58.
----------------------------------------------------------------------------------------------------------------

    With the transfer of two viruses (i.e., severe acute respiratory 
syndrome-related coronavirus, a.k.a. SARS-related coronavirus, and 
reconstructed 1918 influenza virus) from ECCN 1C351.b to 1C351.a by 
this rule, only one virus continues to be controlled under 1C351.b: 
Tick-borne encephalitis virus (Siberian subtype, formerly West Siberian 
virus), which is listed in 1C351.b.3. This rule makes a conforming 
change to ECCN 1C351.b.3 by updating the cross reference therein to 
tick-borne encephalitis virus (Far Eastern subtype, formerly known as 
Russian Spring-Summer encephalitis virus) to reflect the re-designation 
of that virus (now listed under ECCN 1C351.a.53) by the amendments to 
ECCN 1C351.a described above.

Amendments to ECCN 2B352 (Equipment Capable of Use in Handling 
Biological Materials)

    This final rule amends ECCN 2B352 on the CCL to reflect changes to 
the AG ``Control List of Dual-Use Biological Equipment and Related 
Technology and Software'' based on the February 2015 intersessional 
recommendations that were adopted by the AG. Specifically, this rule 
amends the controls on biocontainment chambers, isolators, and 
biological safety cabinets described in 2B352.g.2 to more fully 
identify the characteristics that such equipment must possess in order 
to be controlled under ECCN 2B352. As amended by this rule, ECCN 
2B352.g.2 controls biocontainment chambers, isolators, or biological 
safety cabinets having all of the following characteristics, for normal 
operation: (i) A fully enclosed workspace where the operator is 
separated from the work by a physical barrier; (ii) the ability to 
operate at negative pressure; (iii) the means to safely manipulate 
items in the workspace; and (iv) the supply and exhaust air to and from 
the workspace is high-efficiency particulate air (HEPA) filtered.
    Consistent with the AG intersessional changes described above, this 
rule also adds two notes to ECCN 2B352 to further clarify the scope of 
the controls in 2B352.g.2. Note 1 to ECCN 2B352.g.2 indicates that the 
items subject to these controls include class III biosafety cabinets, 
as specified in the World Health Organization (WHO) Laboratory 
Biosafety Manual (3rd edition, Geneva, 2004) or constructed in 
accordance with national standards, regulations or guidance. Note 2 to 
ECCN 2B352.g.2 indicates that these controls do not apply to isolators 
specially designed for barrier nursing or transportation of infected 
patients.
    This rule also amends the controls on aerosol inhalation equipment 
described in ECCN 2B352.h to include nose-only exposure apparatus. As 
amended by this final rule, ECCN 2B352.h now controls the following 
aerosol inhalation equipment designed for aerosol challenge testing 
with microorganisms, viruses or toxins: (i) Whole-body exposure 
chambers having a capacity of 1 cubic meter or greater; and (ii) nose-
only exposure apparatus utilizing directed aerosol flow and having a 
capacity for the exposure of 12 or more rodents, or 2 or more animals 
other than rodents, and closed animal restraint tubes designed for use 
with such apparatus.
    All items controlled under ECCN 2B352 require a license for CB 
reasons to destinations indicated under CB Column 2 on the Commerce 
Country Chart and for AT reasons to destinations indicated in AT Column 
1 on the Commerce Country Chart.

Amendments to the CCL Based on the June 2015 AG Plenary Understandings

Amendments to ECCN 2B352 (Equipment Capable of Use in Handling 
Biological Materials)

    This final rule also amends ECCN 2B352 on the CCL to reflect 
changes to the AG ``Control List of Dual-Use Biological Equipment and 
Related Technology and Software'' based on the understandings reached 
at the June 2015 AG Plenary meeting. Specifically, this rule amends 
2B352.e to control steam, gas or vapor sterilizable freeze-drying 
equipment with a condenser capacity of 10 kg of ice or greater in 24 
hours (10 liters of water or greater in 24 hours) and less than 1000 kg 
of ice in 24 hours (less than 1,000 liters of water in 24 hours). This 
change is being made in recognition of the increasing viability of gas 
or vapor sterilizable freeze-drying equipment as an efficient and low-
cost alternative to steam sterilization.

Conforming Change to ECCN 1C351 (Human and Animal Pathogens and 
``Toxins'')

    In addition to the AG plenary and intersessional changes described 
above, this rule amends ECCN 1C351 by adding a fifth note to the 
License Requirement Notes in the License Requirements section of this 
ECCN. This new License Requirement Note is intended to provide 
guidance, consistent with the AG ``List of Human and Animal Pathogens 
and Toxins for Export Control,'' in determining whether a particular 
pathogen or ``toxin'' is controlled under ECCN 1C351. License 
Requirement Note 5 reads as follows:

    Biological agents and pathogens are controlled under ECCN 1C351 
when they are an isolated live culture of a pathogen agent, or a 
preparation of a toxin agent that has been isolated or extracted 
from any source or material, including living material that has been 
deliberately inoculated or contaminated with the agent. Isolated 
live cultures of a pathogen agent include live cultures in dormant 
form or in dried preparations, whether the agent is natural, 
enhanced or modified.

Addition of Angola and Burma as States Parties to the Chemical Weapons 
Convention (CWC)

    This rule also amends the EAR to reflect the addition of Angola and 
Burma as States Parties to the CWC on October 16, 2015, and August 7, 
2015, respectively. Specifically, this rule amends Supplement No. 2 to 
part 745 of the EAR (States Parties to the CWC) to add Angola and Burma 
in alphabetical order. Because Angola and Burma are not AG 
participating

[[Page 36461]]

countries, their addition to the list of CWC States Parties in 
Supplement No. 2 to part 745 does not affect the CB Column 1 and CB 
Column 2 license requirements for these countries that are indicated in 
Supplement No. 1 to part 738 of the EAR (Commerce Country Chart). The 
CB Column 3 license requirements indicated for Burma, in the Commerce 
Country Chart, also continue to apply. However, a license is no longer 
required for CB or CW reasons for exports to Angola or Burma of 
mixtures and test kits controlled under ECCN 1C395.a and .b, 
respectively, although a license would be required if any of the end-
user or end-use requirements in part 744 of the EAR apply.
    In order to maintain consistency between the EAR and the Chemical 
Weapons Convention Regulations (CWCR) (15 CFR parts 710-721), with 
respect to those countries that are identified as States Parties to the 
CWC, this rule also amends Supplement No. 1 to part 710 of the CWCR 
(States Parties to the CWC) to add Angola and Burma in alphabetical 
order.

Effect of This Rule on the Scope of the CB Controls in the EAR

    The changes made by this rule only marginally affect the scope of 
the EAR controls on precursor chemicals, human and animal pathogens/
toxins, and equipment capable of use in handling biological materials.
    The amendments to ECCN 1C350, which add the chemical diethylamine 
(C.A.S. 109-89-7), are expected to have only a small impact on the 
scope of the CB controls in this ECCN. This chemical has corrosive 
properties that, in combination with its flammable characteristics, 
cause it to be categorized as a hazardous substance. As such, this 
chemical is regulated by the Occupational Safety and Health 
Administration (OSHA), the Drug Enforcement Administration (DEA), and 
the Environmental Protection Agency (EPA) and also is listed in the 
Department of Transportation's (DOT) Hazardous Materials Table (see 49 
CFR 171.101). For these reasons, together with the limited number of 
commercial applications for this chemical, there is a relatively low 
volume of exports of this chemical from the United States. Therefore, 
the addition of this chemical to ECCN 1C350 is not expected to have a 
significant impact on the number of export license applications that 
must be submitted to BIS for items controlled under this ECCN.
    The scope of the CCL-based CB controls on human and animal 
pathogens and toxins was not affected by the addition of two viruses 
(i.e., severe acute respiratory syndrome-related coronavirus, a.k.a. 
SARS-related coronavirus, and reconstructed 1918 influenza virus) to 
ECCN 1C351.a because these viruses were controlled under ECCN 1C351.b 
prior to the publication of this rule, and the license requirements 
that apply to items listed under 1C351.a are identical to those that 
apply to items listed under 1C351.b. Therefore, these changes are not 
expected to have a significant impact on the number of license 
applications that will have to be submitted for such items.
    The addition of new License Requirement Note 5 to ECCN 1C351 is 
merely intended to provide guidance, consistent with the AG ``List of 
Human and Animal Pathogens and Toxins for Export Control,'' for 
determining whether a particular pathogen or ``toxin'' is controlled 
under this ECCN. It does not affect the scope of the controls of this 
ECCN and, therefore, is not expected to have any discernable effect on 
the number of license applications that will have to be submitted for 
items controlled under ECCN 1C351.
    Although the updates in this rule to the controls on freeze-drying 
(lyophilization) equipment (see ECCN 2B352.e), biocontainment chambers, 
isolators, and biological safety cabinets (see ECCN 2B352.g.2) and 
aerosol inhalation equipment (see ECCN 2B352.h) represent an expansion 
in the number of items that require a license under ECCN 2B352, the 
expanded controls apply to only a relatively small percentage of these 
types of items that were not controlled under ECCN 2B352 prior to the 
publication of this rule. Consequently, any increase in the number of 
license applications resulting from this change is not expected to be 
significant, when considered as a percentage of these types of items.
    Finally, the amendments adding Angola and Burma to Supplement No. 2 
to part 745 of the EAR (States Parties to the CWC) and Supplement No. 1 
to part 710 of the CWCR are expected to have only a small impact on the 
scope of the controls applicable to exports to these countries of items 
on the CCL that are also identified on the AG common control lists. 
Because Angola and Burma are not AG participating countries, the CB 
Column 1 and CB Column 2 license requirements for these countries, as 
indicated in Supplement No. 1 to part 738 of the EAR (Commerce Country 
Chart), continue to apply. In addition, the CB Column 3 license 
requirements indicated for Burma, in the Commerce Country Chart, 
continue to apply. However, under ECCN 1C395, a license is no longer 
required for CB or CW reasons for exports to Angola or Burma of 
mixtures and test kits controlled by ECCN 1C395.a and .b, respectively. 
Therefore, collectively, these changes are expected to result in a 
small decrease in the number of license applications that will have to 
be submitted for these two countries.
    Although the Export Administration Act expired on August 20, 2001, 
the President, through Executive Order 13222 of August 17, 2001, 3 CFR, 
2001 Comp., p. 783 (2002), as amended by Executive Order 13637 of March 
8, 2013, 78 FR 16129 (March 13, 2013), and as extended by the Notice of 
August 7, 2015 (80 FR 48233 (Aug. 11, 2015)), has continued the Export 
Administration Regulations in effect under the International Emergency 
Economic Powers Act (50 U.S.C. 1701 et seq.). BIS continues to carry 
out the provisions of the Export Administration Act, as appropriate and 
to the extent permitted by law, pursuant to Executive Order 13222 as 
amended by Executive Order 13637.

Rulemaking Requirements

    1. Executive Orders 13563 and 12866 direct agencies to assess all 
costs and benefits of available regulatory alternatives and, if 
regulation is necessary, to select regulatory approaches that maximize 
net benefits (including potential economic, environmental, public 
health and safety effects, distributive impacts, and equity). Executive 
Order 13563 emphasizes the importance of quantifying both costs and 
benefits, of reducing costs, of harmonizing rules, and of promoting 
flexibility. This rule has been designated a ``significant regulatory 
action,'' although not economically significant, under section 3(f) of 
Executive Order 12866. Accordingly, the rule has been reviewed by the 
Office of Management and Budget.
    2. Notwithstanding any other provision of law, no person is 
required to respond to, nor shall any person be subject to a penalty 
for failure to comply with, a collection of information subject to the 
requirements of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et 
seq.) (PRA), unless that collection of information displays a currently 
valid Office of Management and Budget (OMB) Control Number. This rule 
contains a collection of information subject to the requirements of the 
PRA. This collection has been approved by OMB under Control Number 
0694-0088 (Multi-Purpose Application), which carries a burden hour 
estimate of 58

[[Page 36462]]

minutes to prepare and submit form BIS-748. Send comments regarding 
this burden estimate or any other aspect of this collection of 
information, including suggestions for reducing the burden, to Jasmeet 
Seehra, Office of Management and Budget, by email to 
Jasmeet_K._Seehra@omb.eop.gov or by fax to (202) 395-7285; and to the 
Regulatory Policy Division, Bureau of Industry and Security, Department 
of Commerce, 14th Street & Pennsylvania Avenue NW., Room 2705, 
Washington, DC 20230 or by email to RPD2@bis.doc.gov.
    3. This rule does not contain policies with Federalism implications 
as that term is defined in Executive Order 13132.
    4. The provisions of the Administrative Procedure Act (5 U.S.C. 
553) requiring notice of proposed rulemaking, the opportunity for 
public participation, and a delay in effective date, are inapplicable 
because this regulation involves a military and foreign affairs 
function of the United States (see 5 U.S.C. 553(a)(1)). Immediate 
implementation of these amendments is non-discretionary and fulfills 
the United States' international obligation to the Australia Group 
(AG). The AG contributes to international security and regional 
stability through the harmonization of export controls and seeks to 
ensure that exports do not contribute to the development of chemical 
and biological weapons. The AG consists of 41 member countries that act 
on a consensus basis and the amendments set forth in this rule 
implement changes made to the AG common control lists (as a result of 
the adoption of the recommendations made at the February 2015 AG 
intersessional meeting and the understandings reached at the June 2015 
AG plenary meeting) and other changes that are necessary to ensure 
consistency with the controls maintained by the AG. Because the United 
States is a significant exporter of the items in this rule, immediate 
implementation of this provision is necessary for the AG to achieve its 
purpose. Any delay in implementation will create a disruption in the 
movement of affected items globally because of disharmony between 
export control measures implemented by AG members, resulting in tension 
between member countries. Export controls work best when all countries 
implement the same export controls in a timely manner.
    Further, no other law requires that a notice of proposed rulemaking 
and an opportunity for public comment be given for this final rule. 
Because a notice of proposed rulemaking and an opportunity for public 
comment are not required to be given for this rule under the 
Administrative Procedure Act or by any other law, the analytical 
requirements of the Regulatory Flexibility Act (5 U.S.C. 601 et seq.) 
are not applicable. Therefore, this regulation is issued in final form.

List of Subjects

15 CFR Part 710

    Chemicals, Exports, Foreign trade, Imports, Treaties.

15 CFR Part 745

    Administrative practice and procedure, Chemicals, Exports, Foreign 
trade, Reporting and recordkeeping requirements.

15 CFR Part 774

    Exports, Reporting and recordkeeping requirements.

    For the reasons stated in the preamble, part 710 of the Chemical 
Weapons Convention Regulations (15 CFR parts 710-721) and parts 745 and 
774 of the Export Administration Regulations (15 CFR parts 730-774) are 
amended as follows:

PART 710--[AMENDED]

0
1. The authority citation for Part 710 continues to read as follows:

    Authority:  22 U.S.C. 6701 et seq.; E.O. 13128, 64 FR 36703, 3 
CFR 1999 Comp., p. 199.

0
2. Supplement No. 1 to Part 710 is amended by revising the undesignated 
center heading ``List of States Parties as of November 1, 2013'' to 
read ``List of States Parties as of June 1, 2016'' and by adding, in 
alphabetical order, the countries ``Angola'' and ``Burma''.

PART 745--[AMENDED]

0
3. The authority citation for Part 745 continues to read as follows:

    Authority:  50 U.S.C. 1701 et seq.; E.O. 12938, 59 FR 59099, 3 
CFR, 1994 Comp., p. 950); Notice of November 12, 2015, 80 FR 70667 
(November 13, 2015).

0
4. Supplement No. 2 to Part 745 is amended by revising the undesignated 
center heading ``List of States Parties as of November 1, 2013'' to 
read ``List of States Parties as of June 1, 2016'' and by adding, in 
alphabetical order, the countries ``Angola'' and ``Burma''.

PART 774--[AMENDED]

0
5. The authority citation for Part 774 continues to read as follows:

    Authority:  50 U.S.C. 4601 et seq.; 50 U.S.C. 1701 et seq.; 10 
U.S.C. 7420; 10 U.S.C. 7430(e); 22 U.S.C. 287c, 22 U.S.C. 3201 et 
seq.; 22 U.S.C. 6004; 30 U.S.C. 185(s), 185(u); 42 U.S.C. 2139a; 43 
U.S.C. 1354; 15 U.S.C. 1824a; 50 U.S.C. 4305; 22 U.S.C. 7201 et 
seq.; 22 U.S.C. 7210; E.O. 13026, 61 FR 58767, 3 CFR, 1996 Comp., p. 
228; E.O. 13222, 66 FR 44025, 3 CFR, 2001 Comp., p. 783; Notice of 
August 7, 2015, 80 FR 48233 (August 11, 2015).

0
6. In Supplement No. 1 to Part 774, Category 1--Special Materials and 
Related Equipment, Chemicals, ``Microorganisms'' and ``Toxins,'' ECCN 
1C350 is amended by revising paragraph d.24 and adding a new paragraph 
d.25 in the ``Items'' paragraph, under the ``List of Items Controlled'' 
section, to read as follows:

Supplement No. 1 to Part 774--The Commerce Control List

* * * * *
1C350 Chemicals that may be used as precursors for toxic chemical 
agents (see List of Items Controlled).
* * * * *

List of Items Controlled

* * * * *
Items:
* * * * *
    d. * * *
    d.24. (C.A.S. #16893-85-9) Sodium hexafluorosilicate;
    d.25. (C.A.S. #109-89-7) Diethylamine.

0
7. In Supplement No. 1 to Part 774 (the Commerce Control List), 
Category 1--Special Materials and Related Equipment, Chemicals, 
``Microorganisms'' and ``Toxins,'' ECCN 1C351 is amended by adding a 
Note 5 to the ``License Requirement Notes,'' under the ``License 
Requirements'' section, and by revising paragraphs a. and b. in the 
``Items'' paragraph, under the ``List of Items Controlled'' section, to 
read as follows:

1C351 Human and animal pathogens and ``toxins'', as follows (see 
List of Items Controlled).

License Requirements

* * * * *
License Requirement Notes: * * *

    5. Biological agents and pathogens are controlled under this 
ECCN 1C351 when they are an isolated live culture of a pathogen 
agent, or a preparation of a toxin agent that has been isolated or 
extracted from any source or material, including living material 
that has been deliberately inoculated or contaminated with the 
agent. Isolated live cultures of a pathogen agent include live 
cultures in dormant form or in dried preparations, whether the agent 
is natural, enhanced or modified.

List of Items Controlled

* * * * *

Items:

    a. Viruses identified on the Australia Group (AG) ``List of 
Human and Animal

[[Page 36463]]

Pathogens and Toxins for Export Control,'' as follows:
    a.1. African horse sickness virus;
    a.2. African swine fever virus;
    a.3. Andes virus;
    a.4. Avian influenza (AI) viruses identified as having high 
pathogenicity (HP), as follows:
    a.4.a. AI viruses that have an intravenous pathogenicity index 
(IVPI) in 6-week-old chickens greater than 1.2; or
    a.4.b. AI viruses that cause at least 75% mortality in 4- to 8-
week-old chickens infected intravenously.
    Note: Avian influenza (AI) viruses of the H5 or H7 subtype that 
do not have either of the characteristics described in 1C352.a.4 
(specifically, 1C352.a.4.a or a.4.b) should be sequenced to 
determine whether multiple basic amino acids are present at the 
cleavage site of the haemagglutinin molecule (HA0). If the amino 
acid motif is similar to that observed for other HPAI isolates, then 
the isolate being tested should be considered as HPAI and the virus 
is controlled under 1C352.a.4.
    a.5. Bluetongue virus;
    a.6. Chapare virus;
    a.7. Chikungunya virus;
    a.8. Choclo virus;
    a.9. Classical swine fever virus (Hog cholera virus);
    a.10. Crimean-Congo hemorrhagic fever virus;
    a.11. Dengue virus;
    a.12. Dobrava-Belgrade virus;
    a.13. Eastern equine encephalitis virus;
    a.14. Ebolavirus (includes all members of the Ebolavirus genus);
    a.15. Foot-and-mouth disease virus;
    a.16. Goatpox virus;
    a.17. Guanarito virus;
    a.18. Hantaan virus;
    a.19. Hendra virus (Equine morbillivirus);
    a.20. Japanese encephalitis virus;
    a.21. Junin virus;
    a.22. Kyasanur Forest disease virus;
    a.23. Laguna Negra virus;
    a.24. Lassa virus;
    a.25. Louping ill virus;
    a.26. Lujo virus;
    a.27. Lumpy skin disease virus;
    a.28. Lymphocytic choriomeningitis virus;
    a.29. Machupo virus;
    a.30. Marburgvirus (includes all members of the Marburgvirus 
genus);
    a.31. Monkeypox virus;
    a.32. Murray Valley encephalitis virus;
    a.33. Newcastle disease virus;
    a.34. Nipah virus;
    a.35. Omsk hemorrhagic fever virus;
    a.36. Oropouche virus;
    a.37. Peste-des-petits ruminants virus;
    a.38. Porcine Teschovirus;
    a.39. Powassan virus;
    a.40. Rabies virus and all other members of the Lyssavirus 
genus;
    a.41. Reconstructed 1918 influenza virus;
    Technical Note: 1C351.a.41 includes reconstructed replication 
competent forms of the 1918 pandemic influenza virus containing any 
portion of the coding regions of all eight gene segments.
    a.42. Rift Valley fever virus;
    a.43. Rinderpest virus;
    a.44. Rocio virus;
    a.45. Sabia virus;
    a.46. Seoul virus;
    a.47. Severe acute respiratory syndrome-related coronavirus 
(SARS-related coronavirus);
    a.48. Sheeppox virus;
    a.49. Sin Nombre virus;
    a.50. St. Louis encephalitis virus;
    a.51. Suid herpesvirus 1 (Pseudorabies virus; Aujeszky's 
disease);
    a.52. Swine vesicular disease virus;
    a.53. Tick-borne encephalitis virus (Far Eastern subtype, 
formerly known as Russian Spring-Summer encephalitis virus--see 
1C351.b.3 for Siberian subtype);
    a.54. Variola virus;
    a.55. Venezuelan equine encephalitis virus;
    a.56. Vesicular stomatitis virus;
    a.57. Western equine encephalitis virus; or
    a.58. Yellow fever virus.
    b. Viruses identified on the APHIS/CDC ``select agents'' lists 
(see Related Controls paragraph #2 for this ECCN), but not 
identified on the Australia Group (AG) ``List of Human and Animal 
Pathogens and Toxins for Export Control,'' as follows:
    b.1. [Reserved];
    b.2. [Reserved]; or
    b.3. Tick-borne encephalitis virus (Siberian subtype, formerly 
West Siberian virus--see 1C351.a.53 for Far Eastern subtype).
* * * * *

0
8. In Supplement No. 1 to Part 774 (the Commerce Control List), 
Category 2--Materials Processing, ECCN 2B352 is amended in the 
``Items'' paragraph, under the List of Items Controlled section, by 
revising paragraph e., by revising paragraph g.2., by adding Notes 1 
and 2 to paragraph g.2., and by revising paragraph h., to read as 
follows:

2B352 Equipment Capable of Use in Handling Biological Materials, as 
Follows (See List of Items Controlled).

* * * * *

List of Items Controlled

* * * * *
Items:
* * * * *
    e. Steam, gas or vapor sterilizable freeze-drying equipment with 
a condenser capacity of 10 kg of ice or greater in 24 hours (10 
liters of water or greater in 24 hours) and less than 1000 kg of ice 
in 24 hours (less than 1,000 liters of water in 24 hours).
* * * * *
    g. * * *
    g.2. Biocontainment chambers, isolators, or biological safety 
cabinets having all of the following characteristics, for normal 
operation:
    g.2.a. Fully enclosed workspace where the operator is separated 
from the work by a physical barrier;
    g.2.b. Able to operate at negative pressure;
    g.2.c. Means to safely manipulate items in the workspace; and
    g.2.d. Supply and exhaust air to and from the workspace is high-
efficiency particulate air (HEPA) filtered.
    Note 1 to 2B352.g.2: 2B352.g.2 controls class III biosafety 
cabinets, as specified in the WHO Laboratory Biosafety Manual (3rd 
edition, Geneva, 2004) or constructed in accordance with national 
standards, regulations or guidance.
    Note 2 to 2B352.g.2: 2B352.g.2 does not control isolators 
``specially designed'' for barrier nursing or transportation of 
infected patients.
    h. Aerosol inhalation equipment designed for aerosol challenge 
testing with microorganisms, viruses or toxins, as follows:
    h.1. Whole-body exposure chambers having a capacity of 1 cubic 
meter or greater.
    h.2. Nose-only exposure apparatus utilizing directed aerosol 
flow and having a capacity for the exposure of 12 or more rodents, 
or two or more animals other than rodents, and closed animal 
restraint tubes designed for use with such apparatus.
* * * * *

    Dated: May 31, 2016.
Kevin J. Wolf,
Assistant Secretary for Export Administration.
[FR Doc. 2016-13271 Filed 6-6-16; 8:45 am]
 BILLING CODE 3510-33-P